ResearcherChengdu Medical CollegeActive in the last 2 years

Ke Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5520-5754; OpenAlex author ID A5100785755. Sources: OpenAlex.

Their work

Papers: 7 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 17

Papers, trials and grants by year

2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 7

Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of locally advanced unresectable or metast… Last author DOI 10.1080/14737140.2025.2576624 ↗
BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer. Co-author DOI 10.4251/wjgo.v17.i7.108274 ↗
Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/ott.s474540 ↗
Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. Last author DOI 10.1097/md.0000000000032364 ↗
Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.04.007 ↗
Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Last author DOI 10.1042/bsr20204301 ↗
GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.11423 ↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yan Feng · 2 shared papers, 2022–2026 · strength 0.72
- Paper Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of… DOI 10.1080/14737140.2025.2576624 ↗
- Paper Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. DOI 10.1097/md.0000000000032364 ↗
Wei Zhou · 2 shared papers, 2021–2025 · strength 0.47
- Paper BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer. DOI 10.4251/wjgo.v17.i7.108274 ↗
- Paper GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. DOI 10.7717/peerj.11423 ↗
Mao Xiao · 1 shared paper, 2025 · strength 0.33
- Paper BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer. DOI 10.4251/wjgo.v17.i7.108274 ↗
Chengyou Du · 2 shared papers, 2021 · strength 0.31
- Paper Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic… DOI 10.1042/bsr20204301 ↗
- Paper GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. DOI 10.7717/peerj.11423 ↗
Tianlei Wang · 1 shared paper, 2024 · strength 0.26
- Paper Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/ott.s474540 ↗
Tao Ren · 1 shared paper, 2024 · strength 0.26
- Paper Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/ott.s474540 ↗
Bo Liu · 1 shared paper, 2021 · strength 0.17
- Paper Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic… DOI 10.1042/bsr20204301 ↗
Tao Ren · 1 shared paper, 2021 · strength 0.14
- Paper GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. DOI 10.7717/peerj.11423 ↗
Bo Liu · 1 shared paper, 2021 · strength 0.14
- Paper GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. DOI 10.7717/peerj.11423 ↗
Lipeng Zhang · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Hu Ren · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Jianwei Zhang · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Chengfeng Wang · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Zongting Gu · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Guotong Qiu · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Yongxing Du · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗
Guang Li · 1 shared paper, 2021 · strength 0.11
- Paper Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreat… DOI 10.1016/j.pan.2021.04.007 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.